Evidence map›Paper›PMID 29029086›Full record

ArticleHealth policy and planning2017

HIV prevention costs and their predictors: evidence from the ORPHEA Project in Kenya.

Omar Galárraga, Richard G Wamai, Sandra G Sosa-Rubí, Mercy G Mugo, David Contreras-Loya, Sergio Bautista-Arredondo, Helen Nyakundi, Joseph K Wang'ombe

Abstract read
In one paragraph

Article in Health policy and planning, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Omar GalárragaSchool of Public Health, Brown University, Providence, RI, USA.
Richard G WamaiGlobal Health Initiative, Northeastern University, Boston, MA, USA.
Sandra G Sosa-RubíHealth Economics Unit, Mexican Institute of Public Health, Cuernavaca, Mexico.
Mercy G MugoDepartment of Economics, University of Nairobi, Nairobi, Kenya.
David Contreras-LoyaSchool of Public Health, University of California at Berkeley, Berkeley, CA, USA.
Sergio Bautista-ArredondoHealth Economics Unit, Mexican Institute of Public Health, Cuernavaca, Mexico.
Helen NyakundiSchool of Public Health, University of Nairobi, Nairobi, Kenya.
Joseph K Wang'ombeSchool of Public Health, University of Nairobi, Nairobi, Kenya.

Funding

Miriam/Brown/Tufts Fogarty AIDS International Training and Research ProgramD43TW000237 · FIC · MIRIAM HOSPITAL · PI CU-UVIN, SUSAN · 1993 to 2014
$10.6M
Spatial Analysis CoreR24HD041020 · NICHD · BROWN UNIVERSITY · PI FOSTER, ANDREW D. · 2001 to 2016
$7.4M
FIC NIH HHS D43 TW000237NICHD NIH HHS R24 HD041020
6 · The paper itself

Abstract

We estimate costs and their predictors for three HIV prevention interventions in Kenya: HIV testing and counselling (HTC), prevention of mother-to-child transmission (PMTCT) and voluntary medical male circumcision (VMMC). As part of the 'Optimizing the Response of Prevention: HIV Efficiency in Africa' (ORPHEA) project, we collected retrospective data from government and non-governmental health facilities for 2011-12. We used multi-stage sampling to determine a sample of health facilities by type, ownership, size and interventions offered totalling 144 sites in 78 health facilities in 33 districts across Kenya. Data sources included key informants, registers and time-motion observation methods. Total costs of production were computed using both quantity and unit price of each input. Average cost was estimated by dividing total cost per intervention by number of clients accessing the intervention. Multivariate regression methods were used to analyse predictors of log-transformed average costs. Average costs were $7 and $79 per HTC and PMTCT client tested, respectively; and $66 per VMMC procedure. Results show evidence of economies of scale for PMTCT and VMMC: increasing the number of clients per year by 100% was associated with cost reductions of 50% for PMTCT, and 45% for VMMC. Task shifting was associated with reduced costs for both PMTCT (59%) and VMMC (54%). Costs in hospitals were higher for PMTCT (56%) in comparison to non-hospitals. Facilities that performed testing based on risk factors as opposed to universal screening had higher HTC average costs (79%). Lower VMMC costs were associated with availability of male reproductive health services (59%) and presence of community advisory board (52%). Aside from increasing production scale, HIV prevention costs may be contained by using task shifting, non-hospital sites, service integration and community supervision.

Indexed as

Circumcision, MaleFemaleHealth FacilitiesHIV InfectionsHumansInfectious Disease Transmission, VerticalKenyaMaleMass ScreeningRetrospective StudiescostseconomicsHIV/AIDS preventionHIV testing and counsellingprevention of mother-to-child transmissionvoluntary medical male circumcision

Identifiers

PMID29029086
PMCPMC5886164

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.